Warning (2): Creating default object from empty value [APP/Controller/WebController.php, line 274]
UTHSCSA Find-A-Study
Photo of Clinical Research Volunteers
Office of the Vice President for Research
FindAStudy :: Human Studies @ UTHSCSA
305  Studies 171  Researchers 29  Categories
× Server Error: Please contact a VPR IT team member for assistance.
× Result: 79 studies found using "cancer"
No studies found - try again with different search terms.
Choose a Category Below to Show a List of Study Titles
  •   Cancers and Other Neoplasms

    •   Brain & Nervous System

      •   A221101 A Phase III Randomized, Double-Blind Placebo Controlled Study of...
        Protocol No.
        HSC20140301H
        Official Title
        A221101 A Phase III Randomized, Double-Blind Placebo Controlled Study of Armodafinil (Nuvigil®) To Reduce Cancer-Related Fatigue in Patients with High Grade Glioma
        Description
        Locations
        UT Health Science Center
        Learn More About This Study

         

      •   ANBL0032, Phase III Randomized Study of Chimeric Antibody 14.18 (Ch14.18) in...
        Protocol No.
        HSC20090466H
        Official Title
        ANBL0032, Phase III Randomized Study of Chimeric Antibody 14.18 (Ch14.18) in High Risk Neuroblastoma Following Myeloablative Therapy and Autologous Stem Cell Rescue
        Description
        Locations
        UT Health Science Center
        Learn More About This Study

         

      •   RTOG 1119 Phase II Randomized Study of Whole Brain Radiotherapy in...
        Protocol No.
        HSC20140321H
        Official Title
        RTOG 1119 Phase II Randomized Study of Whole Brain Radiotherapy in Combination With Concurrent Lapatinib in Patients With Brain Metastasis From HER2-Positive Breast Cancer: A Collaborative Study
        Description
        Locations
        UT Health Science Center
        Learn More About This Study

         

      •   Study of DCVax®-L to Treat Newly Diagnosed GBM Brain Cancer
        Protocol No.
        HSC20120273H
        Official Title
        A Phase III Clinical Trial Evaluating DCVax®-L, Autologous Dendritic Cells Pulsed with Tumor Lysate Antigen for the Treatment of Glioblastoma Multiforme (CTRC# 12-20)
        Description
        The primary purpose of the study is to determine the usefullness of new therapy called DCVax®-L in patients who have newly diagnosed GBM and surgery is planned. Patients must enter screening at a participating site prior to surgical resection of the tumor. Patients will receive the standard of care, including radiation and temozolomide (Temodar) therapy and two out of three will additionally receive DCVax-L, with the remaining one third receiving a placebo. Patients randomized to the placebo arm will have the option to receive DCVax-L in a crossover arm upon documented disease progression. The study will enroll approximately 300 patients from at least 50 cancer centers in the US and UK. In addition to other conditions for enrollment, eligible patients have newly diagnosed, unilateral GBM (grade IV). Participants must have sufficient tumor lysate protein that was generated from the surgically obtained tumor material. Patients must also have sufficient DCVax-L product available after manufacturing.
        Contact
        (210) 450-5816
        Locations
        UT Health Science Center
        Learn More About This Study

         

      •   VB-111 as Treatment for Recurrent Glioblastoma
        Protocol No.
        HSC20110075H
        Official Title
        A Phase I/II Single-Arm Open-Label Multicenter Study of VB-111 in Patients with Recurrent Glioblastoma Multiforme
        Description
        This is a Phase I/II open label, dose escalating, multi-center study. The primary objective is to identify the side effects and effectiveness of VB-111. The study will enroll approximately 35 patients from 3 cancer centers in the US. In addition to other conditions for enrollment, eligible patients have diagnosis of glioblastoma multiforme or gliosarcoma that has become worse after treatment with radiation and temozolomide, but are otherwise in good health. Adult patients who have a history of prior treatment with bevacizumab, aflibercept or similar drug may not be eligible to enroll. In addition, a recent cardiac event, active vascular disease, or vascular retinopathy may not be allowed for enrollment.
        Contact
        (210) 450-5964
        Locations
        UT Health Science Center
        Learn More About This Study

         

    •   Breast - Female

      •   Increasing Access of Latinas into Breast Cancer Clinical Trials
        Protocol No.
        HSC20090165H
        Official Title
        Increasing Access of Latinas into Breast Cancer Clinical Trials
        Description
        Locations
        UT Health Science Center
        Learn More About This Study

         

      •   Quality of life following breast conservation therapy versus mastectomy with...
        Protocol No.
        HSC20130002H
        Official Title
        Quality of life following breast conservation therapy versus mastectomy with reconstruction in women with primary breast cancer (CTRC#12-0091)
        Description
        Locations
        UT Health Science Center
        Learn More About This Study

         

      •   Study of LEE011 and/or BYL719 plus Letrozole in Advanced ER-positive Breast...
        Protocol No.
        HSC20140065H
        Official Title
        A Phase Ib/II, Multicenter, Study of the Combination of LEE011 and BYL719 with Letrozole in Adult Patients with Advanced ER+ Breast Cancer (CTRC# 13-0054)
        Description
        This Phase 1/2 study is designed to evaluate the safety and effectiveness of two new drugs, LEE011 and BYL719, when combine individually and together with an old drug, letrozole, when treating advanced ER-positive breast cancer. The primary objective is to identify the best dose of LEE011 and BYL719 to use when combined with letrozole. The study will enroll approximately 300 patients from at least 32 cancer centers in the USA, Australia, France, China, Israel, Italy, and Spain. In addition to other conditions for enrollment, eligible female patients are postmenopausal, have ER-positive, HER2-negative advanced breast cancer. Patients who have a history of more than 1 prior chemotherapy regimen, brain metastases, pancreatitis, impaired cardiac function, diabetes mellitus or other severe medical conditions may not be eligible to enroll.
        Locations
        UT Health Science Center
        Learn More About This Study

         

      •   Tamoxifen, Letrozole, Anastrozole, or Exemestane With or Without...
        Protocol No.
        HSC20110363H
        Official Title
        S1007 - A Phase III, Randomized Clinical Trial of Standard Adjuvant Endrocrine Therapy +/- Chemotherapy in Patients with 1-3 Positive Nodes, Hormone Receptor-Positive and HER2-Negative Breast Cancer with Recurrence Score (RS) of 25 or Less
        Description
        The purpose of this study is studying whether giving tamoxifen citrate, anastrozole, letrozole, or exemestane works better with or without chemotherapy when treating patients with breast cancer. The results of this study will show whether giving tamoxifen citrate, anastrozole, letrozole, or exemestane is more effective when taken with combination chemotherapy. Estrogen can cause the growth of breast cancer cells. Hormone therapy, such as tamoxifen citrate, may fight breast cancer by blocking the use of estrogen by the tumor cells. Drugs such as anastrozole, letrozole, and exemestane may fight breast cancer by lowering the amount of estrogen the body makes. Drugs used in chemotherapy work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from reproducing. The primary objective is to determine the effect of the treatment in invasive disease-free survival (DFS) of women with node-positive breast cancer treated with endocrine therapy with vs without chemotherapy. The study will enroll 9,400 participants from many cancer centers in the US. In addition to other conditions for enrollment, women with a diagnosis of invasive breast cancer, 1 to 3 positive lymph nodes, estrogen receptor  and/or progesterone receptor positive, and HER-2 negative.  Eligible patients have had surgery and completed radiotherapy, if it was recommended.
        Contact
        450-1886
        Locations
        UT Health Science Center
        Learn More About This Study

         

    •   Breast - Female, Breast - Male

      •   A Phase III, Open Label, Randomised, Controlled, Multi-Centere Study to...
        Protocol No.
        HSC20140399H
        Official Title
        A Phase III, Open Label, Randomised, Controlled, Multi-Centere Study to Assess the Efficacy and Safety of Olaparib Monotherapy Versus Physician''s Choice Chemotherapy in the Treatment of Metastatic Breast Cancer Patients with Germline BRCA1/2 Mutations
        Description
        Contact
        210-450-5715
        Locations
        UT Health Science Center
        Learn More About This Study

         

    •   Buccal Cavity and Pharnyx

      •   Texas Cancer Diagnostics Pipeline: Oral Cancer Subproject
        Protocol No.
        HSC20110108H
        Official Title
        Texas Cancer Diagnostics Pipeline: Oral Cancer Subproject
        Description
        Contact
        210-450-0739
        Locations
        UT Health Science Center
        Learn More About This Study

         

    •   Cervix, Other female genital

      •   Standard Versus Intensity-Modulated Pelvic Radiation Therapy in Treating...
        Protocol No.
        HSC20130196H
        Official Title
        RTOG 1203 A Randomized Phase III Study of Standard vs IMRT Pelvic Radiation for Post-Operative Treatment of Endometrial and Cervical Cancer (TIME-C) (CTRC#13-0004)
        Description
        This Phase III study evaluates two different methods of radiation, comparing the side effects and the effectiveness, when used as treatment for endometrial and cervical cancer after surgery. The primary objective is to evaluate and compare the acute gastrointestinal side effects of IMRT vs standard radiotherapy. The study will enroll approximately 281 patients many cancer centers in the US. In addition to other conditions for enrollment, eligible patients have endometrial or cervical cancer, have undergone a hysterectomy, and are otherwise in good health. Patients who have a history of bladder control problems, prior radiation to the pelvis, active inflammatory bowel disease, cardiac history, infection, prior treatment with platinum-based chemotherapy, or insufficient liver function may not be eligible to enroll.
        Locations
        UT Health Science Center
        Learn More About This Study

         

    •   Colon

      •   A Phase II, Multicenter, Randomized, Double-Blind Study to Evaluate the...
        Protocol No.
        HSC20140356H
        Official Title
        A Phase II, Multicenter, Randomized, Double-Blind Study to Evaluate the Efficacy and Safety of RO5520985 Plus Folfox Versus Bevacizumab Plus Folfox in Patients with Previously Untreated Metastatic Colorectal Cancer
        Description
        Contact
        (210) 450-5966
        Locations
        UT Health Science Center
        Learn More About This Study

         

      •   Modulation of Autophagy: A Clinical Study of Vorinostat Plus...
        Protocol No.
        HSC20150178H
        Official Title
        Modulation of Autophagy: A Clinical Study of Vorinostat Plus Hydroxychloroquine Versus Regorafenib in Refractory Metastatic Colorectal Cancer (mCRC) Patients (CTMS# 14-2015)
        Description
        Contact
        (210) 450-5962
        Locations
        UT Health Science Center
        Learn More About This Study

         

      •   SWOG S0820, Adenoma and Second Primary Colorectal Cancer Prevention Trial...
        Protocol No.
        HSC20130412H
        Official Title
        S0820 - A Double Blind Placebo-Controlled Trial of Eflornithine and Sulindac to Prevent Recurrence of High Risk Adenomas and Second Primary Colorectal Cancers in Patients with Stage 0-III Colon Cancer, Phase III - Preventing Adenomas of the Colon with Eflornithine and Sulindac (PACES) (CTRC#13-0036)
        Description
        The study is designed to investigate whether eflornithine, sulindac or both are effective in preventing or delaying adenomas and second primary colorectal cancers in patients previously treated for Stages 0 through III colon cancer. The primary objective is to assess whether eflornithine and/or sulindac are effective in reducing the recurrence rate at 3 years. The study will enroll approximately 1340 participants from hundreds of cancer centers in the US. In addition to other conditions for enrollment, eligible patients have a history of stage 0-III colon cancer that was surgically removed up to 1 year previously; rectosigmoid cancers are eligible if no prior radiation therapy, no evidence of cancer by colonoscopy exam at time of study entry, and able to take oral medications. Patients who have a history of uncontrolled hypertension or gastric/duodenal ulcer within past year or other medical conditions may not be eligible to enroll.
        Locations
        UT Health Science Center
        Learn More About This Study

         

    •   Esophagus

      •   A Two Part, Phase 1, Multi-Center, Open-Label Study of DKN-01 in Combination...
        Protocol No.
        HSC20140189H
        Official Title
        A Two Part, Phase 1, Multi-Center, Open-Label Study of DKN-01 in Combination with Weekly Paclitaxel; Arm A: A Dose-Escalation Study in Patients with Relapsed or Refractory Esophageal Cancer or Gastro-Esophageal Junction Tumors; Arm B: An Expansion Cohort in Patients with Relapsed or Refractory Esophageal Cancer or Gastro-Esophageal Junction Tumors
        Description
        Contact
        (210) 450-1912
        Locations
        UT Health Science Center
        Learn More About This Study

         

    •   Kidney

      •   An Open-Label, Non-Randomized, Multicentre, Comparative, Phase I Study to...
        Protocol No.
        HSC20150093H
        Official Title
        An Open-Label, Non-Randomized, Multicentre, Comparative, Phase I Study to Determine the Pharmacokinetics, Safety and Tolerability of AZD9291 Following A Single Oral Dose to Patients with Advanced Solid Tumours and Normal Hepatic Function or Mild or Moderate Hepatic Impairment
        Description
        Contact
        210-450-5976
        Locations
        UT Health Science Center
        Learn More About This Study

         

      •   COG 9442: National Wilm''s Tumor Study #5 Late Effects
        Protocol No.
        HSC19960123H
        Official Title
        COG 9442: National Wilm''s Tumor Study #5 Late Effects
        Description
        Locations
        UT Health Science Center
        Learn More About This Study

         

      •   Everolimus vs Nothing as Treatment for Kidney Cancer After Kidney Surgery
        Protocol No.
        HSC20110362H
        Official Title
        S0931 - EVEREST: EVErolimus for Renal Cancer Ensuing Surgical Therapy, A Phase III Study
        Description
        The purpose of this study is to see how well everolimus works as a prevention treatment for kidney cancer patients who have undergone surgery to remove all or part of a kidney. The primary objective is to determine if everolimus works better than taking nothing for preventing kidney cancer from coming back after surgery. The study will enroll 1170 participants from many cancer centers in the US. In addition to other conditions for enrollment, patients have a diagnosis of renal cell or clear cell kidney cancer but no evidence of cancer in other parts of the body.  Eligible patients have recovered from the kidney surgery and have not received any other treatment for their cancer.  Eligible patients are able to take oral medications and do not have any digestive problem that would affect how well a drug is digested.  Patients are not eligible if they have uncontrolled diabetes, impaired liver function, or impaired breathing function.
        Locations
        UT Health Science Center
        Learn More About This Study

         

    •   Leukemia, other

      •   TREX2''s Role in the Development of MDS and AML
        Protocol No.
        HSC20140441H
        Official Title
        TREX2''s Role in the Development of MDS and AML
        Description
        Locations
        UT Health Science Center
        Learn More About This Study

         

    •   Liver

      •   HepaSphere/Quadrasphere Microspheres for Delivery of Doxorubicin for the...
        Protocol No.
        HSC20120330H
        Official Title
        Phase 3 Prospective, Randomized, Blinded and Controlled Investigation of Hepasphere/Quadrasphere Microspheres for Delivery of Doxorubicin for the Treatment of Hepatocellular Cancer
        Description
        The purpose of this study is to evaluate overall survival in patients treated with HepaSphere/Quadrasphere compared to conventional transarterial chemoembolization with particle PVA. Eligible adult patients have a diagnosis of hepatocellular cancer and are not currently or previously treated with chemo- or radiation therapy or sorafenib. Estimated Enrollment: 520 from multiple cancer centers in the US and Europe.
        Locations
        UT Health Science Center
        Learn More About This Study

         

      •   Pharmacokinetics of Oral Alisertib (MLN8237) in Adult Patients With Advanced...
        Protocol No.
        HSC20140397H
        Official Title
        Pharmacokinetics of Oral Alisertib (MLN8237) in Adult Patients With Advanced Solid Tumors or Relapsed/Refractory Lymphoma With Varying Degrees of Hepatic Function
        Description
        Locations
        UT Health Science Center
        Learn More About This Study

         

    •   Lung

      •   Carboplatin & Paclitaxel With or Without Bevacizumab and/or Cetuximab in...
        Protocol No.
        HSC20120217H
        Official Title
        S0819 - A Randomized, Phase III Study Comparing Carboplatin/Paclitaxel or Carboplatin/Paclitaxel/Bevacizumab With or Without Concurrent Cetuximab in Patients With Advanced Non-Small Cell Lung Cancer (NSCLC) (CTRC# 12-24)
        Description
        The purpose of this study is to compare how well treatment with carboplatin and paclitaxel with or without bevacizumab works with or without cetuximab as therapy for patients with stage IV or recurrent non-small cell lung cancer. The primary objective is to compare overall survival (up to 3 years) based on the different treatment used. The study will enroll 1,700 participants from many cancer centers in the US. In addition to other conditions for enrollment, eligible patients have newly diagnosed stage IV lung cancer or their lung cancer has recurred after prior surgery and/or radiation therapy. Study participants have not been previously treated with chemotherapy or bevacizumab.
        Locations
        UT Health Science Center
        Learn More About This Study

         

      •   Hypofractionated Image-Guided Radiation Therapy (IGRT) for patients with...
        Protocol No.
        HSC20120093H
        Official Title
        Phase III Randomized Study of Standard versus Accelerated Hypofractionated Image-Guided Radiation Therapy (IGRT) in Patients with Stage II-III Non-Small Cell Lung Cancer and Poor Performance Status
        Description
        The study is designed to determine whether an accelerated course of hypofractionated radiation therapy with daily image guidance and motion assessment/control will allow more effective treatment of poor performance status patients with stage II-III non-small cell lung cancer (NSCLC), who would benefit from local therapy compared to standard radiation therapy (60 Gy in 2 Gy per fraction). The primary objective is to compare one type of radiation therapy with another type in order to determine if one is better than the other.    The study will enroll approximately 226 patients from 5 cancer centers in Texas. In addition to other conditions for enrollment, eligible patients have state II or III NSCLC and are otherwise in good health. Patients who have a history of radiotherapy to the area that overlaps the area to be treated may not be eligible to enroll.
        Locations
        UT Health Science Center
        Learn More About This Study

         

      •   Radiation Therapy, Carboplatin, and Paclitaxel with or without Veliparib in...
        Protocol No.
        HSC20130133H
        Official Title
        S1206, A Dose Finding Study Followed by Phase II Randomized, Placebo-Controlled Study of Veliparib (ABT-888) Added to Chemotherapy with Carboplatin and Paclitaxel for Unresectable Stage III Non-Small Cell Lung Cancer (NSCLC) (CTRC# 12-0094)
        Description
        This phase I/II partially randomized trial studies the side effects and best dose of veliparib when given together with radiation therapy, carboplatin, and paclitaxel and to see how well it works in treating patients with stage III non-small cell lung cancer that cannot be removed by surgery. Veliparib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Radiation therapy uses high energy x rays to kill tumor cells. Drugs used in chemotherapy, such as carboplatin and paclitaxel, work in different ways to stop the growth of tumor cells either by killing the cells or by stopping them from dividing. It is not yet known whether radiation therapy, carboplatin, and paclitaxel are more effective with or without veliparib in treating non-small cell lung cancer. The study will enroll approximately 132 patients from many cancer centers in the US.
        Locations
        UT Health Science Center
        Learn More About This Study

         

    •   Lymphoid Leukemia

      •   A Phase I Trial of SGN-CD70A In Patients with CD70-Positive Malignancies
        Protocol No.
        HSC20140423H
        Official Title
        A Phase I Trial of SGN-CD70A In Patients with CD70-Positive Malignancies
        Description
        Contact
        (210) 450-5816
        Locations
        UT Health Science Center
        Learn More About This Study

         

    •   Multiple Myeloma

      •   A Phase 1B Multicenter, Open-Label, Dose-Escalation Study to Determine the...
        Protocol No.
        HSC20140438H
        Official Title
        A Phase 1B Multicenter, Open-Label, Dose-Escalation Study to Determine the Maximum Tolerated Dose, Safety, and Antitumor Activity of an Alternative Liquid Formulation of ACY-1215 (Ricolinostat) in Combination with Pomalidomide and Low-Dose Dexamethasone in Patients with Relapsed-and-Refractory Multiple Myeloma
        Description
        Locations
        UT Health Science Center
        Learn More About This Study

         

      •   A Phase 1B/2 Multi-Center Open Label, Dose-Escalation Study to Determine the...
        Protocol No.
        HSC20140261H
        Official Title
        A Phase 1B/2 Multi-Center Open Label, Dose-Escalation Study to Determine the Maximum Tolerated Dose, Safety, and Efficacy of Acy-1215 in Combination with Pomalidomide and Low-Dose Dexamethasone in Patients with Relapsed-and-Refractory Multiple Myeloma
        Description
        Locations
        UT Health Science Center
        Learn More About This Study

         

      •   BT062 in Combination with Lenalidomide and Dexamethasone as Treatment for...
        Protocol No.
        HSC20120168H
        Official Title
        A Phase I/IIa Multi-Dose Escalation Study of BT062 in Combination with Lenalidomide and Dexamethasone in Subjects with Relapsed or Relapsed/Refractory Multiple Myeloma (CTRC# 12-09)
        Description
        This is a two-part study. The Phase I part of the study is a dose-escalation study designed to evaluate the safety and tolerability of BT026 when used in combination with lenalidomide and dexamethasone.  The Phase II part of the study is designed to evaluate the effectiveness of the 3-drug combination when treating patients with relapsed or refractory multiple myeloma. The study will enroll up to 18 patients in Part 1 and up to 31 patients in Part 2 from 4 cancer centers in the US. In addition to other conditions for enrollment, eligible patients are those whose disease has become worse in spite of treatment and who are otherwise in good health. Eligible patients are able to swallow capsules and comply with taking oral medications. Adult patients who have a history of blood clots, active infection including hepatitis, uncontrolled hypertension, heart attack or other cardiac complications may not be eligible to enroll.
        Contact
        (210) 450-5902
        Locations
        UT Health Science Center
        Learn More About This Study

         

    •   Multiple sites

      •   A Group-wide Process for Collecting Long Term Follow Up Data
        Protocol No.
        HSC20030245H
        Official Title
        A Group-wide Process for Collecting Long Term Follow Up Data
        Description
        This protocol is not an independent research study, but rather a means to aggregate Children''s Cancer Group protocols that are closed to patient entry for the purpose of collecting current status information on those patients treated under those protocols.
        Contact
        210-567-7462
        Locations
        UT Health Science Center
        Learn More About This Study

         

      •   A Phase 0, Investigator Initiated Study, Evaluating the Impact of COX2...
        Protocol No.
        HSC20130426H
        Official Title
        A Phase 0, Investigator Initiated Study, Evaluating the Impact of COX2 Inhibition on Human Sera Biomarkers from Obese Subjects (CTRC#13-0041)
        Description
        Locations
        UT Health Science Center
        Learn More About This Study

         

      •   A Phase 1 Study of CBL0137 in Patients with Metastatic or Unresectable...
        Protocol No.
        HSC20130328H
        Official Title
        A Phase 1 Trial of CBL0137 In patients With Metastatic or Unresectable Advanced Solid Neoplasms or Refractory Lymphomas (CTRC# 13-0031)
        Description
        This Phase 1 study is designed to determine the best dose of CBL0137 to use when treating patients with metastatic or unresectable advanced solid tumors or lymphoma. The study will enroll up to 48 patients from at least 2 cancer centers in the US. In addition to other conditions for enrollment, eligible patients have cancer that has not improved or has come back after prior treatment and are otherwise in good health. Patients who have a history of active infection, cancer involving the central nervous system, a particular EKG abnormality or other serious medical conditions may not be eligible to enroll.
        Contact
        (210) 450-5902
        Locations
        UT Health Science Center
        Learn More About This Study

         

      •   A Phase 1 Study to Evaluate MEDI4736 at Treatment for Advanced Malignant...
        Protocol No.
        HSC20120299H
        Official Title
        A Phase 1/2 Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of MEDI4736 in Subjects with Advanced Solid Tumors (CTRC#12-0061)
        Description
        This Phase I study is designed to evaluate MEDI4736 in advanced cancer patients. The primary objective is to determine the best dose of MEDI4736 to use when treating patients with metastatic or unresectable advanced solid tumors. The study will enroll approximately 90 patients from at least 5 cancer centers in the US. In addition to other conditions for enrollment, eligible patients have advanced malignant melanoma, renal cell carcinoma, non-small cell lung cancer, or colorectal cancer that has not responded to standard therapy and for which no standard therapy exists. Patients who have a history of treatment with an anti-PD-1 agent/antibody, tuberculosis, hepatitis A, B, or C infection, symptomatic or untreated central nervous system disease or other severe medical conditions may not be eligible to enroll.  
        Contact
        (210) 450-1912
        Locations
        UT Health Science Center
        Learn More About This Study

         

      •   A Phase 1, Dose Escalation Study of MLN7243 in Adult Patients with Advanced...
        Protocol No.
        HSC20140098H
        Official Title
        A Phase I, Open-Label, Multicenter, Dose Escalation Study to Assess the Safety and Tolerability of MLN7243, an Inhibitor of Ubiquitin-Activating Enzyme (UAE), in Adult Patients With Advanced Solid Tumors
        Description
        This Phase 1 is designed to evaluate safety, tolerability, and antitumor effectiveness of MLN7243 in adult patients with advanced cancer. The primary objective is to identify the best dose of MLN7243 to use in treating cancer. The study will enroll approximately 119 patients from at least 2 cancer centers in the US. In addition to other conditions for enrollment, eligible patients have advanced cancer for which no standard therapy is available and otherwise in good health. Patients who have a history of cardiac impairment, brain metastases, active infection, or other severe medical conditions may not be eligible to enroll.
        Contact
        (210) 450-5966
        Locations
        UT Health Science Center
        Learn More About This Study

         

      •   A Phase 1, First-In-Human Study of Escalating Doses of Oral TVB-2640 In...
        Protocol No.
        HSC20140398H
        Official Title
        A Phase 1, First-In-Human Study of Escalating Doses of Oral TVB-2640 In Patient With Solid Tumors
        Description
        Contact
        (210) 450-5595
        Locations
        UT Health Science Center
        Learn More About This Study

         

      •   A Phase 1, Open-Label, Dose Escalation, Multi-Center Study of ACT-PFK-158,...
        Protocol No.
        HSC20150170H
        Official Title
        A Phase 1, Open-Label, Dose Escalation, Multi-Center Study of ACT-PFK-158, 2HCl in Patients with Advanced Solid Tumors (CTMS# 14-2014)
        Description
        Locations
        UT Health Science Center
        Learn More About This Study

         

      •   A Phase II, Open-Label, Multi-Center Study of ANG1005 in Her2+ Breast Cancer...
        Protocol No.
        HSC20140206H
        Official Title
        A Phase II, Open-Label, Multi-Center Study of ANG1005 in Her2+ Breast Cancer Patients with Recurrent Brain Metastases
        Description
        Contact
        (210) 450-5964
        Locations
        UT Health Science Center
        Learn More About This Study

         

      •   ANUR1131, Music Video for AYA-Parent Communication and Resilience (CTRC#13-0023)
        Protocol No.
        HSC20110484H
        Official Title
        ANUR1131, Music Video for AYA-Parent Communication and Resilience (CTRC#13-0023)
        Description
        Locations
        UT Health Science Center
        Learn More About This Study

         

      •   Circulating Tumor Cells in Pediatric Solid Tumors
        Protocol No.
        HSC20150037H
        Official Title
        Circulating Tumor Cells in Pediatric Solid Tumors
        Description
        Locations
        UT Health Science Center
        Learn More About This Study

         

      •   Crizotinib in cancer patients with liver function impairment
        Protocol No.
        HSC20120328H
        Official Title
        A Phase 1 Study to Evaluate the Effect of Hepatic Impairment on the Pharmacokinetics and Safety of Crizotinib in Advanced Cancer Patients (CTRC#12-0059 )
        Description
        This Phase I study is designed to evaluate the potential effect of hepatic impairment on the pharmacokinetic profile and safety of crizotinib in advanced cancer patients. The primary objective is to compare the amount of drug in the blood between the different groups of patients with various degrees of liver function. The study will enroll approximately 50 from at least 4 cancer centers in the US. In addition to other conditions for enrollment, eligible patients have advanced cancer with mild, moderate or severe liver dysfunction as well as patients with normal liver function. Patients who have a history of uncontrolled ascites, prior treatment with crizotinib, spinal cord compression, congestive heart failure, severe lung disease, infection, or other severe medical conditions may not be eligible to enroll.
        Contact
        (210) 450-1912
        Locations
        UT Health Science Center
        Learn More About This Study

         

      •   Dose Escalating Study of IMGN853 for Patients with Cancer
        Protocol No.
        HSC20120333H
        Official Title
        A Phase 1, First-in-Human Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of IMGN853 in Adults with Ovarian Cancer and other FOLR1- Positive Solid Tumors (CTRC# 12-0064)
        Description
        The purpose of this study is to determine the best dose of IMGN853 to use when treating people with cancer, in particular, ovarian cancer, that has spread to other areas in the body and/or cannot be removed surgically. The primary objective is to identify the side effects and right dose of IMGN853 and to find out if IMGN853 works as a treatment for patients with specific types of cancer. The study will enroll approximately 64 participants from no more than 6 cancer centers in the US. In addition to other conditions for enrollment, eligible adult patients are those whose tumors have become worse in spite of treatment and who otherwise are in good health.  The tumors of all potential participants will be tested for the presence of a specific protein and results of the test will help determine if the patient is a candidate for treatment with IMGN853. Likely tumors are those that began in the ovary or fallopian tube, but some types of lung cancer and kidney cancer might also have this protein present. Participants cannot have a history of bone marrow transplant, cornea (eye) problems, active infection, significant heart history, multiple sclerosis or nerve damage.
        Contact
        (210) 450-5966
        Locations
        UT Health Science Center
        Learn More About This Study

         

      •   Epidemiology of MRI-confirmed Cardiac Late Effects in Anthracycline Exposed...
        Protocol No.
        HSC20140173H
        Official Title
        Epidemiology of MRI-confirmed Cardiac Late Effects in Anthracycline Exposed Survivors of Childhood Cancer
        Description
        Locations
        UT Health Science Center
        Learn More About This Study

         

      •   Hydroxychloroquine + Vorinostat in Advanced Solid Tumors
        Protocol No.
        HSC20080462H
        Official Title
        Inhibition of Autophagy in Solid Tumors: A Phase I Pharmacokinetic and Pharmacodynamic Study of Hydroxychloroquine in Combination with the HDAC Inhibitor SAHA for the Treatment of Patients with Advanced Solid Tumors with an expansion study in advanced Renal and Colorectal Cancer (CTRC# 08-52)
        Description
        This study is designed to evaluate   hydroxychloroquine (HCQ) with vorinostat the safety and antitumor activity of   this drug combination in advanced cancer patients. The primary objective is to determine   the best dose and evaluate the safety and effectiveness of this drug   combination. The study will enroll   approximately 48 from one cancer center in San Antonio. In addition to other conditions   for enrollment, eligible patients have cancer that has not improved or has   come back after prior treatment but are otherwise in good health. After identifying   the best dose is identified, only patients with advanced renal cell cancer   and colorectal cancer will be enrolled. Patients who have a history of prior   treatment with vorinostat, hepatitis or active infections, inability to take   oral medication, gastrointestinal disorder that affects complete digestion or   other severe medical conditions may not be eligible to enroll.  
        Contact
        (210) 450-5966
        Locations
        UT Health Science Center
        Learn More About This Study

         

      •   Improving Quality of Life Among Hispanic/Latino Breast, Colorectal &...
        Protocol No.
        HSC20110094H
        Official Title
        Improving Quality of Life Among Hispanic/Latino Breast, Colorectal & Prostate Cancer Survivors: A Randomized Control Trial of Patient Navigators Using the LIVESTRONG SurvivorCare Program
        Description
        Locations
        UT Health Science Center
        Learn More About This Study

         

      •   Incidence and Factors Associated with the Development and Severity of Oral...
        Protocol No.
        HSC20050218H
        Official Title
        Incidence and Factors Associated with the Development and Severity of Oral Mucositis in Patients Undergoing High Dose Chemotherapy and Peripheral Stem Cell Transplantation
        Description
        Locations
        UT Health Science Center
        Learn More About This Study

         

      •   MRX34 as treatment for patients with unresectable liver cancer or metastatic...
        Protocol No.
        HSC20130176H
        Official Title
        A Multicenter Phase I Study of MRX34, MicroRNA miR-RX34 Liposomal Injection (CTRC# 12-0110)
        Description
        This Phase I study is designed to evaluate the safety of MRX34 in patients with primary liver cancer or those with liver metastasis from other cancers. The primary objective is to identify the side effects of MRX34. The study will enroll approximately 48 patients at two cancer centers in Texas. In addition to other conditions for enrollment, eligible patients have liver cancer or advanced metastatic cancer with liver metastasis that cannot be removed surgically and are otherwise in good health. Patients who have a history of infection including hepatitis, bleeding problems, central nervous system involvement, or require anticoagulant therapy may not be eligible to enroll.
        Contact
        (210) 450-5964
        Locations
        UT Health Science Center
        Learn More About This Study

         

      •   New Cancer Diagnosis Costs and Follow up Patterns for Uninsured vs Insured...
        Protocol No.
        HSC20140018H
        Official Title
        New Cancer Diagnosis Costs and Follow up Patterns for Uninsured vs Insured Patients: A Quality Improvement Project (CTRC#13-0038)
        Description
        Locations
        UT Health Science Center
        Learn More About This Study

         

      •   Observing Patients with Cancer Receiving Zoledronic Acid for Bone Metastases
        Protocol No.
        HSC20090363H
        Official Title
        S0702: A Prospective Observational Multicenter Cohort Study to Assess the Incidence of Osteonecrosis of the Jaw (ONJ) in Cancer Patients with Bone Metastases Starting Zoledronic Acid Treatment
        Description
        The purpose of this study is to observe patients with cancer who are receiving zoledronic acid for bone metastases to see if they get osteonecrosis of the jaw.  The primary objective is to identify when a diagnosis of osteonecrosis of the jaw happens.  The study will enroll 3,500 participants from many cancer centers in the US. In addition to other conditions for enrollment, eligible patients are those who are planning to start taking zoledronic acid (Zometa®) for metastatic bone disease. Study participants cannot have had radiation therapy to the maxilla (upper jawbone). Participation in other studies or therapies is allowed.
        Locations
        UT Health Science Center
        Learn More About This Study

         

      •   Phase 1 Study of Carfilzomib in Patients with Advanced Cancers and Various...
        Protocol No.
        HSC20130446H
        Official Title
        An Open-Label, Single Arm, Phase 1 Study of the Pharmacokinetics and Safety of Carfilzomib in Subjects with Advanced Malignancies and Varying Degrees of Hepatic Impairment (CTRC#13-0043)
        Description
        The purpose of this study is to compare the safety and effectiveness of carfilzomib, a drug that has not been FDA approved and is still in investigational status. The objective is to measure the amount of the drug in the blood at specific times following dosing. This study is being done in people with varying degrees of liver function to see if they respond differently to the study drug. The study will enroll approximately 40 from at least 3 cancer centers in the US. In addition to other conditions for enrollment, eligible patients have advanced cancer, either solid tumor or hematologic malignancy as well as chronic liver impairment that has been stable with no sudden worsening within one month prior to enrollment. Patients who have a history of inadequate kidney function, congestive heart failure or other serious heart condition, brain metastasis, chronic infection, or other severe medical conditions may not be eligible to enroll.
        Contact
        (210) 450-5816
        Locations
        UT Health Science Center
        Learn More About This Study

         

      •   Phase I Study of BAX69 for Patients with Solid Tumors
        Protocol No.
        HSC20120141H
        Official Title
        A Phase 1 Open-Label Study to Assess the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of BAX69 in Subjects with Malignant Solid Tumors (CTRC# 12-03)
        Description
        The purpose of this study is to determine the best dose of BAX69 to use when treating people with cancer that has spread to other areas in the body and/or cannot be removed surgically. The primary objective is to identify the side effects of BAX69 and to find out if BAX69 works as a treatment for cancer patients. The study will enroll approximately 32 to 44 participants from a several cancer centers in the US. In addition to other conditions for enrollment, eligible patients are those whose tumors have become worse in spite of treatment and who are otherwise in good health.  Adult patients who have a history of cancer involving the central nervous system (brain), recent heart problems, uncontrolled blood pressure problems, recent major surgery, inflammatory arthritis, or hepatitis may not be eligible to enroll.
        Contact
        (210) 450-5902
        Locations
        UT Health Science Center
        Learn More About This Study

         

      •   Phase I Study to Evaluate the Effect of LDE225 on the Pharmacokinetics of...
        Protocol No.
        HSC20130180H
        Official Title
        A Phase Ib, Multi-Center, Two Parallel Group, Open-Label, Drug-Drug Interaction Study to Assess the Effect of LDE225 on the Pharmacokinetics of Bupropion and Warfarin in Patients with Advanced Solid Tumors (CTRC# 12-0111)
        Description
        This Phase I study is designed to evaluate a possible drug-drug interaction between LDE225 on warfarin and bupropion in patients with advanced cancer.   The primary objective is to determine if LDE225 has a drug interaction with bupropion and warfarin.    The study will enroll approximately 60 patients at several cancer centers in the US. In addition to other conditions for enrollment, eligible patients have advanced cancer that has become worse in spite of therapy and are otherwise in good health. Patients who have a history of brain metastases, bleeding disorders, neuromuscular disorders, infection including hepatitis, or are already on bupropion (Wellbutrin), warfarin (Coumadin), or vitamin K therapy may not be eligible to enroll.
        Contact
        (210) 450-5902
        Locations
        UT Health Science Center
        Learn More About This Study

         

      •   Phase Ib study of BGJ398 in combination with BYL719 in patients with...
        Protocol No.
        HSC20140022H
        Official Title
        A phase Ib, open-label study of oral BGJ398 in combination with oral BYL719 in adult patients with select advanced solid tumors
        Description
        This Phase 1 study is designed to evaluate the combination of BGJ398 and BYL719. in patients with cancers that have a specific genetic mutation. The objective of the study is to determine the safety and effectiveness of the combination of BGJ398 and BYL719. The primary objective of the study is to evaluate the safety and effectiveness of the combination of BGJ398 with BYL719 in patients whose tumors express mutations to PIK3CA In addition to other conditions for enrollment, eligible patients have cancer that has not improved or has come back after prior treatment and are otherwise in good health. Patients with diabetes mellitus, particularly those requiring treatment with insulin, may not be eligible. The study will enroll approximately 55 patients from at least 27 cancer centers in the US, Europe, and Asia.
        Contact
        (210) 450-5595
        Locations
        UT Health Science Center
        Learn More About This Study

         

      •   Prognostic and predictive markers in patients with advanced metastatic tumors
        Protocol No.
        HSC20130219H
        Official Title
        Numeration and Single-Cell Molecular Profiling of Circulating Tumor Cells as Prognostic and Predictive Marker In Patients with Advanced Metastatic Tumors (CTRC#13-0001)
        Description
        This study will research possible associations between circulating tumor cells (CTC) quantities or gene profile characteristics and clinical outcomes. The primary objective is to obtain blood samples from participants over an 8-week period for research analysis.  The study will enroll approximately 200 patients at the CTRC. In addition to other conditions for enrollment, eligible patients have advanced metastatic cancer.
        Locations
        UT Health Science Center
        Learn More About This Study

         

      •   SCUSF1202 [prev. ACCL1032], A Randomized Controlled Trial of Acupressure to...
        Protocol No.
        HSC20130271H
        Official Title
        SCUSF1202 [prev. ACCL1032], A Randomized Controlled Trial of Acupressure to Control Chemotherapy-Induced Nausea in Children Receiving Highly Emetogenic Chemotherapy (previously ACCL1032)
        Description
        Locations
        UT Health Science Center
        Learn More About This Study

         

    •   Non-Hodgkin's Lymphoma

      •   IMGN529 as Treatment for Patients with Advanced Non-Hodgkin''s Lymphoma
        Protocol No.
        HSC20130331H
        Official Title
        A Phase I, Multi-center, Open-label Study of IMGN529 Administered Intravenously in Adult Patients with Relapsed or Refractory Non-Hodgkin''s Lymphoma (CTRC#13-0025)
        Description
        This Phase 1 study is designed to evaluate the safety and tolerability of IMGN529 when used to treat patients with relapsed or refractory non-Hodgkin''s lymphoma (NHL). The study will enroll approximately 46 patients from at least 5 cancer centers in the US and Switzerland. In addition to other conditions for enrollment, eligible patients have relapsed or refractory non-Hodgkin''s lymphoma that has not improved or has come back after prior treatment and are otherwise in good health. Patients who have a history of allogeneic stem cell transplantation or known lymphoma involving the central nervous system, including brain metastases, or other severe medical conditions may not be eligible to enroll.
        Contact
        (210) 450-5966
        Locations
        UT Health Science Center
        Learn More About This Study

         

    •   Other Digestive Organ, Stomach

      •   A021202 - Prospective Randomized Phase II Trial of Pazopanib (NSC# 737754,...
        Protocol No.
        HSC20150052H
        Official Title
        A021202 - Prospective Randomized Phase II Trial of Pazopanib (NSC# 737754, IND 75648) Versus Placebo in Patients with Progressive Carcinoid Tumors (CTRC 14-0046)
        Description
        Contact
        450-1886
        Locations
        UT Health Science Center
        Learn More About This Study

         

    •   Other Respiratory and Intrathoracic Organs

      •   A Randomized, Double-Blind Phase 2 Study of Ruxolitinib or Placebo in...
        Protocol No.
        HSC20140479H
        Official Title
        A Randomized, Double-Blind Phase 2 Study of Ruxolitinib or Placebo in Combination with Pemetrexed/Cisplatin and Pemetrexed Maintenance for Initial Treatment of Subjects with Nonsquamous Non-Small Cell Lung Cancer That Is Stage IIIB, Stage IV, or Recurrent
        Description
        Contact
        (210) 450-1804
        Locations
        UT Health Science Center
        Learn More About This Study

         

    •   Pancreas

      •   A Phase 2 Trial of MLN0264 in Previously Treated Patients With Advanced or...
        Protocol No.
        HSC20140455H
        Official Title
        A Phase 2 Trial of MLN0264 in Previously Treated Patients With Advanced or Metastatic Pancreatic Adenocarcinoma Expressing Guanylyl Cyclase C (GCC)
        Description
        Contact
        (210) 450-1912
        Locations
        UT Health Science Center
        Learn More About This Study

         

      •   M402 plus gemcitabine compared to gemcitabine alone as treatment for...
        Protocol No.
        HSC20120151H
        Official Title
        A Phase I/II, Two-Part, Multicenter Study to Evaluate the Safety and Efficacy of M402 in Combination with nab-Paclitaxel and Gemcitabine in Patients with Metastatic Pancreatic Cancer (CTRC# 12-11)
        Description
        This is a Phase I/II study comparing gemcitabine alone to gemcitabine plus M402 as treatment for metastatic pancreatic cancer.  The primary objective is to compare overall survival in patients treated with M402 in combination with gemcitabine compared with gemcitabine alone. The study will enroll approximately 138 patients from 6 cancer centers in the US. In addition to other conditions for enrollment, eligible patients are those whose pancreatic cancer has become spread but has not been treated with chemotherapy and who are otherwise in good health. Adult patients who have a history of treatment with gemcitabine, blood clotting disorders, needing anti-platelet therapy, coronary artery disease, active infection including hepatitis B or C may not be eligible to enroll.
        Contact
        (210) 450-5902
        Locations
        UT Health Science Center
        Learn More About This Study

         

    •   Prostate

      •   Biomarkers and clinical parameters associated with Gleason score upgrading
        Protocol No.
        HSC20140367H
        Official Title
        Biomarkers and clinical parameters associated with Gleason score upgrading
        Description
        Locations
        UT Health Science Center
        Learn More About This Study

         

      •   Canary Prostate Active Surveillance Study (PASS)
        Protocol No.
        HSC20080303H
        Official Title
        Canary Prostate Active Surveillance Study (PASS)
        Description
        Locations
        UT Health Science Center
        Learn More About This Study

         

      •   Castration Compared to Castration Plus Metformin as First Treatment for...
        Protocol No.
        HSC20110273H
        Official Title
        Phase II, Randomized,Placebo Controlled, Double Blind, Prospective Study of Castration Compared to Castration Plus Metformin as First Line Treatment for Patients with Advanced Prostate Cancer (IDD# 10-21)
        Description
        This is a Phase II double blind study comparing castration alone vs castration plus metformin. Double blind means neither the patient nor the doctor know whether the study participant is getting metformin or the placebo.  The primary objective is to determine if adding metformin to castration is better or different compared to castration alone. The study will enroll 94 patients at the CTRC. In addition to other conditions for enrollment, eligible patients have metastatic prostate cancer that require castration therapy by using either an LHRH analogue or surgical castration and are otherwise in good health. Men who have a history of inadequate heart, kidney, or liver function, serious infections, alcohol abuse, or lactic/metabolic acidosis may not be eligible to enroll.
        Locations
        UT Health Science Center
        Learn More About This Study

         

      •   Dynamic Multi-Cohort Prediction Modeling of Prostate Biopsy Outcome
        Protocol No.
        HSC20150050H
        Official Title
        Dynamic Multi-Cohort Prediction Modeling of Prostate Biopsy Outcome
        Description
        Locations
        UT Health Science Center
        Learn More About This Study

         

      •   Establishing Community-Based Normal Distributions of Selected Urinary Biomarkers
        Protocol No.
        HSC20110312H
        Official Title
        Establishing Community-Based Normal Distributions of Selected Urinary Biomarkers
        Description
        Locations
        UT Health Science Center
        Learn More About This Study

         

      •   Hormonal Therapy plus Radiation Therapy as Treatment for Prostate Cancer
        Protocol No.
        HSC20130062H
        Official Title
        RTOG 0924 Androgen Deprivation Therapy and High Dose Radiotherapy With or Without Whole-Pelvic Radiotherapy in Unfavorable Intermediate or Favorable High Risk Prostate Cancer: A Phase III Randomized Trial
        Description
        The purpose of this study is determine which type of anti-hormonal therapy and radiation therapy will result in an improvement in survival in patients with “unfavorable” intermediate risk or “favorable” high risk prostate cancer.  The risk is the possibility or chances of the prostate cancer coming back after being treated. The primary objective is to see which treatment improves the duration of survival. The study will enroll 2,580 participants from many cancer centers in the US. In addition to other conditions for enrollment, men who were diagnosed with prostate cancer within the past 180 days and have no evidence of lymph node involvement by CT scan or MRI within the past 90 days may be enrolled. Men are not eligible for this study if the prostate or testes have been surgically removed. Men who have already been treated with brachytherapy or radiation to the pelvis or hormonal therapy are not enrolled. Patients with a history of other cancers may not be eligible.
        Locations
        UT Health Science Center
        Learn More About This Study

         

      •   Identification of Protein and Genetic Biomarkers of Prostate Cancer and Risk...
        Protocol No.
        HSC20020380H
        Official Title
        Identification of Protein and Genetic Biomarkers of Prostate Cancer and Risk Factors for Progression of Disease
        Description
        Locations
        UT Health Science Center
        Learn More About This Study

         

      •   Improving Prostate Biopsy Efficiency: The Finasteride Challenge Test
        Protocol No.
        HSC20100352H
        Official Title
        Improving Prostate Biopsy Efficiency: The Finasteride Challenge Test
        Description
        Locations
        UT Health Science Center
        Learn More About This Study

         

      •   Symptom Management in Prostate Cancer Survivors: Cancer-Related Fatigue,...
        Protocol No.
        HSC20130013H
        Official Title
        Symptom Management in Prostate Cancer Survivors: Cancer-Related Fatigue, Quality Of Life and Physical Function in Prostate Cancer Survivors
        Description
        Locations
        UT Health Science Center
        Learn More About This Study

         

    •   Soft Tissue

      •   YONDELIS® (trabectedin) as Treatment for Locally Advanced or Metastatic Soft...
        Protocol No.
        HSC20130148H
        Official Title
        A Multicenter, Open-Label Single-Arm Study of YONDELIS® (trabectedin) for Subjects With Locally Advanced or Metastatic Soft Tissue Sarcoma Who Have Relapsed or Are Refractory to Standard of Care Treatment (CTRC#12-0107)
        Description
        The purpose of this study is to facilitate access to trabectedin for eligible, previously treated patients with soft tissue sarcoma, excluding liposarcoma and leiomyosarcoma (L-type sarcoma), who cannot be expected to benefit from currently available therapeutic options but who may benefit from treatment with trabectedin. The safety profile of trabectedin will be evaluated to further assess the potential risks of trabectedin treatment. The study will enroll approximately 3,000 patients from at least 36 cancer centers in the US, Canada, and Israel. In addition to other conditions for enrollment, eligible patients are at least 15 years old, have soft tissue sarcoma excluding liposarcoma and leiomyosarcoma (L-type soft tissue sarcoma) that cannot be surgically removed and is in an advanced stage or has spread. Patients who have symptomatic viral hepatitis or chronic liver disease, a significant uncontrolled cardiac condition, active infection, or other severe medical conditions may not be eligible to enroll.
        Locations
        UT Health Science Center
        Learn More About This Study

         

    •   Urinary Bladder

      •   Evaluating responses to intravesical BCG administration to patients with...
        Protocol No.
        HSC20140002H
        Official Title
        Evaluating responses to intravesical BCG administration to patients with invasive bladder cancer: Defining mechanisms of mTOR inhibition to boost immunotherapy in bladder cancer and Improving immunotherapy in bladder cancer by targeting immune dysfunction
        Description
        Locations
        UT Health Science Center
        Learn More About This Study

         

      •   Standard or Extended Pelvic Lymph Node Surgery as Part of Treatment for...
        Protocol No.
        HSC20110462H
        Official Title
        S1011: A Phase III Surgical Trial to Evaluate the Benefit of a Standard Versus an Extended Pelvic Lymphadenectomy Performed at Time of Radial Cystectomy for Muscle Invasive Urothelial Cancer (IDD# 11-46)
        Description
        This purpose of this study is to determine whether standard surgery to remove the pelvic lymph nodes works the same, better, or worse than extended pelvic lymph node removal when treating patients with surgery for invasive bladder cancer. The primary objective is to compare the difference, if there is any, in the length of time it takes bladder cancer to come back and/or spread to other parts of the body in patients who have been diagnosed with muscle-invasive bladder cancer who are undergoing surgery to remove the entire bladder.  Study participants will have either extended pelvic lymph node removal or standard pelvic lymph node removal. The study will enroll 620 participants from many cancer centers in the US. In addition to other conditions for enrollment, patients have urothelial cancer of the bladder and require surgery for definitive treatment.  Eligible patients have not had prior surgery to remove part of the bladder or any pelvic lymph node s. Eligible patients have not had prior pelvic radiation therapy.
        Locations
        UT Health Science Center
        Learn More About This Study

         

      •   Surveillance for low and low-intermediate-risk non-muscle invasive bladder...
        Protocol No.
        HSC20130177H
        Official Title
        Surveillance for low and low-intermediate-risk non-muscle invasive bladder cancer: A Pilot Study (CTRC#12-0108)
        Description
        Locations
        UT Health Science Center
        Learn More About This Study

         

  •   Genetics

    •   Development of potential response to radiation phenotypes (RRPs) for genetic...
      Protocol No.
      HSC20130198H
      Official Title
      Development of potential response to radiation phenotypes (RRPs) for genetic studies: a pilot study
      Description
      Although cancer treatment with radiation can produce high cure rates, adverse effects often result from radiotherapy. Therefore, the major objective of this pilot project is to develop potential response to radiation phenotypes (RRPs) and to explore their genetic basis.
      Contact
      210-258-9532
      Locations
      UT Health Science Center
      Learn More About This Study

       

    •   Genetic Epidemiology of Lung Cancer: Genetic markers associated with gender,...
      Protocol No.
      HSC20090349H
      Official Title
      Genetic Epidemiology of Lung Cancer: Genetic markers associated with gender, age and smoking history
      Description
      Although smoking is a known contributing risk factor for developing lung cancer we believe other factors may also be associated with this condition. The incidence of lung cancer in women has continued to rise over the past several decades despite a declining incidence in men. The increase in lung cancer in women has been, in part, explained by an increase in smoking in women, however, we believe certain hormonal factors, along with specific genetic factors may influence the development of lung cancer. The researchers are interested in finding better ways to detect lung cancer, to treat it, and, if possible, to prevent the occurrence of lung cancer. More information is needed in order to determine what causes lung cancer and how lung cancer is related to heredity. Lung cancer may result from genetic factors – things passed on to us from our ancestors that we, in turn, pass onto our children.
      Contact
      210-562-9123
      Locations
      UT Health Science Center
      Learn More About This Study

       

  •   Healthy Subjects Needed

    •   Immune Tests in Blood to Study Estrogens and Immune Co-Signal Effects on...
      Protocol No.
      HSC20110472H
      Official Title
      Immune Tests in Blood to Study Estrogens and Immune Co-Signal Effects on Immune Function in Age
      Description
      This study will help understand why immunity differs between men and women and how differences change over time. These data will help understand why women are more prone to autoimmunity, and how to use immune therapy effectively in different age groups and sexes. We will also test specific immune defects seen in mouse models of autoimmunity and cancer to determine if these defects also occur in humans.
      Contact
      450-1439
      Locations
      UT Health Science Center
      Learn More About This Study

       

    •   Viral Reporters to Determine Circulating Tumor Cells Level and Viability in...
      Protocol No.
      HSC20140107H
      Official Title
      Viral Reporters to Determine Circulating Tumor Cells Level and Viability in Patients with Bladder Cancer: A Pilot Study
      Description
      Blood and Urine Samples Needed From Bladder Cancer Patients and Healthy Volunteers
      Contact
      210-716-1055
      Locations
      UT Health Science Center
      Learn More About This Study

       

  •   Heart, Vascular and Blood

    •   Air Force Villages Aging Study
      Protocol No.
      HSC20080234H
      Official Title
      Air Force Villages Aging Study
      Description
      The purpose of this study is to study protein changes and other biomarkers in the blood that occur with aging. Over the past decade, advances in biomedical science and technology have led to the development of state-of-the-art laboratory techniques for studying proteins in a blood sample. This is called comparative proteomics, where researchers compare hundreds, even thousands, of proteins in the blood for people with different diseases. For example, it has been used to identify cancer in people without having to have a biopsy, which is a needle that is used to get tissue from the inside of the body. Until now, comparative proteomics has only been used in animals to study changes in proteins with aging. We believe that by applying these methods in humans, we can better understand what happens inside the body as a person ages. We believe this information (how the proteins from a blood sample change with age) can help us to find ways in which we can help people age successfully and remain independent into late life.
      Contact
      210-617-5197
      Locations
      UT Health Science Center
      Learn More About This Study

       

  •   Minority Studies

    •   Persistent tanning as a novel adaptation to ultraviolet radiation in...
      Protocol No.
      HSC20130334H
      Official Title
      Persistent tanning as a novel adaptation to ultraviolet radiation in Indigenous Americans
      Description
      A study of tanning response in Mexican American individuals. We want to learn whether an individual’s ability to tan and the length of time that tan persists is related to Native American ancestry and specific genes. We are testing the hypothesis that increased tanning may have evolved in Native Americans to adapt to intense ultraviolet radiation (UVR) in tropical and subtropical regions. We are interested in tanning response because it is a risk factor for skin cancer and vitamin D deficiency, a risk factor for a number of diseases.
      Contact
      210-258-9470
      Locations
      UT Health Science Center
      Learn More About This Study

       

  •   Women's Health

    •   ENLACE: A Promotora-Led Physical Activity Intervention Trial for Latinas in...
      Protocol No.
      HSC20110460H
      Official Title
      ENLACE: A Promotora-Led Physical Activity Intervention Trial for Latinas in Texas
      Description
      A research study of the promotion of physical activity. Latino women in the United States have among the highest rates of overweight and sedentary lifestyle. Both of these are important risk factors for heart disease, diabetes, high cholesterol and some cancers. Increasing daily physical activity can prevent weight gain and improve overall health and mental well-being. In partnership with communities, the researchers hope to determine the most effective methods for promoting physical activity among women.
      Contact
      210-562-6514
      Locations
      UT Health Science Center
      Learn More About This Study